Shopping Cart 0
Cart Subtotal
USD 0

ArQule Inc (ARQL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including activated checkpoint therapy platform and c-met survival protein platform. Its lead product candidate, ARQ 197 (tivantinib), an inhibitor of the c-Met receptor tyrosine kinase, is undergoing clinical-stage development. The other product pipeline of the company includes ARQ 087 is a multi-kinase inhibitor, ARQ 092 is an Akt inhibitor, ARQ 751 is a next-generation inhibitor of Akt, ARQ 761 is an activator of the damage response pathway, ARQ 531 is a B-cell malignancies and ARQ 087 is an inhibitor of fibroblast growth factor receptor. ArQule is headquartered in Burlington, Massachusetts, the US.

ArQule Inc (ARQL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ArQule Inc, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

ArQule Raises USD15.7 Million in Private Placement of Common Stock 11

Partnerships 12

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12

Licensing Agreements 13

Basilea Pharma Enters into Licensing Agreement with ArQule 13

Roivant Sciences Enters into Licensing Agreement with ArQule 14

Equity Offering 15

ArQule Raises USD70 Million in Public Offering of Shares 15

ArQule to Raise Funds in Secondary Offering of Shares 17

ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18

ArQule to Raise Up to USD30 Million in Issue of Shares 19

ArQule Raises USD15.3 Million in Private Placement of Shares 20

ArQule Completes Public Offering Of Common Stock For USD 60 Million 21

ArQule Inc-Key Competitors 23

ArQule Inc-Key Employees 24

ArQule Inc-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

Oct 31, 2018: ArQule reports third quarter 2018 financial results 26

Aug 01, 2018: ArQule Reports Second Quarter 2018 Financial Results 28

May 07, 2018: ArQule Reports First Quarter 2018 Financial Results 30

Nov 09, 2017: ArQule Reports Third Quarter 2017 Financial Results 32

Aug 04, 2017: ArQule Reports Second Quarter 2017 Financial Results 34

May 03, 2017: Arqule Reports First Quarter 2017 Financial Results 35

Mar 07, 2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results 36

Corporate Communications 38

May 24, 2018: ArQule Announces Two Key Appointments 38

Product News 39

06/07/2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases 39

06/03/2017: ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology Annual Meeting 40

05/17/2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting 41

03/15/2018: ArQule to Present Data on Derazantinib 42

Product Approvals 43

Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome 43

Clinical Trials 44

Mar 15, 2018: ArQule to Provide Update on ARQ 751 44

Nov 21, 2017: ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma 45

Jul 11, 2017: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies 46

Jun 23, 2017: ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 47

May 18, 2017: ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 48

May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting 49

May 17, 2017: ArQule to Present Clinical Data on ARQ-761 at the 2017 American Society of Clinical Oncology Annual Meeting 50

Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ArQule Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ArQule Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ArQule Raises USD15.7 Million in Private Placement of Common Stock 11

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12

Basilea Pharma Enters into Licensing Agreement with ArQule 13

Roivant Sciences Enters into Licensing Agreement with ArQule 14

ArQule Raises USD70 Million in Public Offering of Shares 15

ArQule to Raise Funds in Secondary Offering of Shares 17

ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18

ArQule to Raise Up to USD30 Million in Issue of Shares 19

ArQule Raises USD15.3 Million in Private Placement of Shares 20

ArQule Completes Public Offering Of Common Stock For USD 60 Million 21

ArQule Inc, Key Competitors 23

ArQule Inc, Key Employees 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ArQule Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including activated checkpoint therapy platform and c-met survival protein platform. Its lead product candidate, ARQ 197 (tivantinib), an inhibitor of the c-Met receptor tyrosine kinase, is undergoing clinical-stage development. The other product pipeline of the company includes ARQ 087 is a multi-kinase inhibitor, ARQ 092 is an Akt inhibitor, ARQ 751 is a next-generation inhibitor of Akt, ARQ 761 is an activator of the damage response pathway, ARQ 531 is a B-cell malignancies and ARQ 087 is an inhibitor of fibroblast growth factor receptor. ArQule is headquartered in Burlington, Massachusetts, the US.

ArQule Inc (ARQL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ArQule Inc, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

ArQule Raises USD15.7 Million in Private Placement of Common Stock 11

Partnerships 12

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12

Licensing Agreements 13

Basilea Pharma Enters into Licensing Agreement with ArQule 13

Roivant Sciences Enters into Licensing Agreement with ArQule 14

Equity Offering 15

ArQule Raises USD70 Million in Public Offering of Shares 15

ArQule to Raise Funds in Secondary Offering of Shares 17

ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18

ArQule to Raise Up to USD30 Million in Issue of Shares 19

ArQule Raises USD15.3 Million in Private Placement of Shares 20

ArQule Completes Public Offering Of Common Stock For USD 60 Million 21

ArQule Inc-Key Competitors 23

ArQule Inc-Key Employees 24

ArQule Inc-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

Oct 31, 2018: ArQule reports third quarter 2018 financial results 26

Aug 01, 2018: ArQule Reports Second Quarter 2018 Financial Results 28

May 07, 2018: ArQule Reports First Quarter 2018 Financial Results 30

Nov 09, 2017: ArQule Reports Third Quarter 2017 Financial Results 32

Aug 04, 2017: ArQule Reports Second Quarter 2017 Financial Results 34

May 03, 2017: Arqule Reports First Quarter 2017 Financial Results 35

Mar 07, 2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results 36

Corporate Communications 38

May 24, 2018: ArQule Announces Two Key Appointments 38

Product News 39

06/07/2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases 39

06/03/2017: ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology Annual Meeting 40

05/17/2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting 41

03/15/2018: ArQule to Present Data on Derazantinib 42

Product Approvals 43

Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome 43

Clinical Trials 44

Mar 15, 2018: ArQule to Provide Update on ARQ 751 44

Nov 21, 2017: ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma 45

Jul 11, 2017: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies 46

Jun 23, 2017: ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 47

May 18, 2017: ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 48

May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting 49

May 17, 2017: ArQule to Present Clinical Data on ARQ-761 at the 2017 American Society of Clinical Oncology Annual Meeting 50

Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ArQule Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ArQule Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ArQule Raises USD15.7 Million in Private Placement of Common Stock 11

ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12

Basilea Pharma Enters into Licensing Agreement with ArQule 13

Roivant Sciences Enters into Licensing Agreement with ArQule 14

ArQule Raises USD70 Million in Public Offering of Shares 15

ArQule to Raise Funds in Secondary Offering of Shares 17

ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18

ArQule to Raise Up to USD30 Million in Issue of Shares 19

ArQule Raises USD15.3 Million in Private Placement of Shares 20

ArQule Completes Public Offering Of Common Stock For USD 60 Million 21

ArQule Inc, Key Competitors 23

ArQule Inc, Key Employees 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ArQule Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.